Drug resistant focal epilepsy related to focal cortical dysplasia research hub

A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

This study looks at a new medicine called PTI5803 for people with difficult-to-treat epilepsy caused by focal cortical dysplasia. Researchers want to find out if taking this add-on treatment over a longer period is safe, well-tolerated, and helpful for reducing seizures and improving daily quality of life.